The development of regorafenib and its current and potential future role in cancer therapy

Drugs of Today

Volumn 49, Issue 2, 2013, Pages 105-115

  Davis, S L ^a   Eckhardt, S G ^a   Messersmith, W A ^a   Jimeno, A ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Gastrointestinal stromal tumor; Metastatic colorectal cancer; Multikinase inhibitor; Regorafenib; Tyrosine kinase inhibitor

Indexed keywords

ANGIOPOIETIN RECEPTOR; B RAF KINASE; BEVACIZUMAB; CETUXIMAB; CISPLATIN; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FLT3 LIGAND; FLUOROPYRIMIDINE; IMATINIB; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PEMETREXED; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN RET; RAF PROTEIN; REGORAFENIB; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ALOPECIA; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER THERAPY; CELL PROLIFERATION; COLORECTAL CANCER; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; IC 50; KIDNEY CARCINOMA; KIDNEY FAILURE; LIVER CELL CARCINOMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PAIN; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; STEADY STATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOICE CHANGE;

GASTROINTESTINAL STROMAL TUMOR; METASTATIC COLORECTAL CANCER; MULTIKINASE INHIBITOR; REGORAFENIB; TYROSINE KINASE INHIBITOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; NEOPLASMS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 84874725276     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.2.1930525     Document Type: Article

References (37)

1. Aust, D.E., Sommer, U., Baretton, G.B. What can molecular pathology offer for optimal decision making? Ann Oncol 2012, 23(10): x63-x70.
2. Petrelli, A., Giordano, S. From single to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 2008, 15(5): 422-32.
3. Demetri, G.D. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. Semin Oncol 2011, 38(Suppl. 1): S10-9.
4. Dematteo, R.P., Ballman, K.V., Antonescu, C.R. et al. Adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373(9669): 1097-104.
5. Motzer, R.J., Hutson, T.E., Tomczak, P. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinomA. J Clin Oncol 2009, 27 (22): 3584-90.
6. Escudier, B., Eisen, T., Stadler, W.M. et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27(20): 3312-8.
7. Rini, B.I., Escudier, B., Tomczak, P. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378(9807): 1931-9.
8. Sternberg, C.N., Davis, I.D., Mardiak, J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010: 28(6): 1061-8.
9. Llovet, J.M., Ricci, S., Mazzaferro, V., et al. Sorafenib in advanced hepatocellular carcinomA. N Engl J Med 2008, 359(4): 378-90.
10. Kwak, E.L., Bang, Y.J., Camidge, D.R. et al. Analplastic lymphoma kinase inhibition in non-small-cell lung canceR. N Eng J Med 2010, 363(18): 1693-703.
11. Fukuoka, M., Wu, Y.L., Thongprasert, S. et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefinitib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29(21): 2866-74.
12. Rosell, R., Carcereny, E., Gervais, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-smallcell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13(3): 239-46.
13. FDA approves new treatment for advanced colorectal cancer (news release). U.S. Food and Drug Administration, September 27, 2012. www.fdA.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm321271.htm. Accessed November 13, 2012.
14. Wilhelm, S.M., Dumas, J., Adnane, L. et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal, and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011, 129(1): 245-55.
15. Kane, R.C., Farrell, A.T., Saber, H. et al. Sorafenib for the treatment of advanced renal cell carcinomA. Clin Cancer Res 2006, 12(24): 7271-8.
16. Kane, R.C., Farrell, A.T., Madabushi, R. et al. Sorafenib for the treatment of unresectable hepatocellular carcinomA. Oncologist 2009, 14(1): 95-100.
17. Wilhelm, S.M., Carter, C., Tang, L. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64(19): 7099-109.
18. Carr, B.I., Cavallini, A., Lippolis, C. et al. Fluoro-sorafenib (regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol 2013, 228(2): 292-7.
19. Mross, K., Frost, A., Steinbild, S. et al. A phase I dose-escalation study of regorafeinb (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 2012, 18(9): 2658-67.
20. Therasse, P., Arbuck, S.G., Eisenhauer, E.A. et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92(3): 205-16.
21. Strumberg, D., Scheulen, M.E., Schultheis, B. et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer 2012, 106(11): 1722-7.
22. Shimizu, T., Tolcher, A.W., Patnaik, A. et al. Phase I doseescalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors. J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 3035.
23. Kies, M.S., Blumenschein, G.R., Christensen O. et al. Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients with advanced refractory non-small cell lung cancer (NSCLC). J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 7585.
24. Schultheis, B., Folprecht, G., Kuhlmann, J. et al. Phase I study of regorafenib sequentially administered with either FOLFOX or FOLFIRI in patients with first-/second-line colorectal canceR. J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 3585.
25. Determination of safety, efficacy, and pharmacokinetics of "regorafenib" combined with pemetrexed and cisplatin in patients with nonsquamous non-small cell lung cancer (NCT01187615). ClinicalTrials.gov Web site. Accessed November 10, 2012.
26. George, S., Wang, Q., Heinrich, M. et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a mluticenter phase II trial. J Clin Oncol 2012, 30(19): 2401-7.
27. Eisen, T., Joensuu, H., Nathan, P.D. et al. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol 2012, 13(10): 1055-62.
28. Safety study of BAY73-4506 in patients with hepatocellular carcinoma (NCT01003015). ClinicalTrials.gov Web site. Accessed November 17, 2012.
29. Regorafenib + FOLFIRI versus placebo + FOLFIRI as 2nd line tx in metastatic colorectal cancer (NCT01298570). ClinicalTrials.gov Web site. Accessed November 10, 2012.
30. First line treatment of metastatic colorectal cancer with mFOLFOX6 in combination with regorafenib (NCT01289821). ClinicalTrials.gov Web site. Accessed November 17, 2012.
31. Grothey, A., Sobrero, A.F., Siena, S. et al. Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients with metastatic colorectal cancer who have progressed after standard therapies. J Clin Oncol [Gastrointest Cancers Symp (Jan 19-21, San Francisco) 2012] 2012, 30(Suppl. 4): Abst LBA385.
32. Van Cutsem, E., Sobrero, A.F., Siena, S. et al. Phase III CORRECT trial of regorafenib in metastatic colorectal canceR. J Clin Oncol [48th Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2012] 2012, 30(Suppl): Abst 3502.
33. Stivarga [package insert]. Bayer HealthCare Pharmaceuticals Inc. (Wayne, NJ) 2012.
34. Demetri, G.D., Reichardt, P., Kang, Y. et al. Randomized phase III trial of regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib and sunitinib: GRID trial. J Clin Oncol 48th Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2012] 2012, 30(18, Suppl.): Abst LBA10008.
35. Ziv-Aflibercept. www.fdA.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ ucm314438.htm Accessed January 19, 2013.
36. Van Cutsem, E., Tabernero, J., Lakomy, R. et al. Intravenous aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (mCRC): results of a multinational phase III trial. Ann Oncol [13th World Congr Gastrointest Cancer (June 22-25, Barcelona) 2011] 2011, 22(Suppl. 5): Abst O-0024.
37. Wolchok, J.D., Hoos, A., O'Day, S. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteriA. Clin Cancer Res 2009, 15(23): 7412-20.